How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

254 results for

Alpha-Hydroxy acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Efficacy and Safety of Maralixibat (SHP625) in the Treatment of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC)

of bile acid synthesis (serum 7 alpha-hydroxy-4-cholesten-3-one [C4]). Evaluate the safety of SHP625 [ Time Frame: Baseline up to Week 26 ] Adverse events, changes in vital signs, laboratory, and other safety parameters will be compared between participants on active treatment vs. placebo. Plasma Levels of Maralixibat Over Time [ Time Frame: Baseline, Week 6, 10, 14, 18, 22 and 26 ] Systemic concentrations of maralixibat in plasma will be assessed. Eligibility Criteria Go to Information from (...) : Treatment Response as Measured by the Observer Itch Reported Outcome (ItchRO[Obs]) and Serum Bile Acids (sBA) [ Time Frame: Baseline up to Week 26 ] Compare the percentage of participants on active treatment versus (vs.) placebo who meet response criteria which is defined as improvement in average before midday (AM) Observer Itch Reported Outcome (ItchRO[Obs]) severity decrease from baseline and normalization or reduction from baseline sBA demonstrated on at least 2 of the last 3 study visits

2017 Clinical Trials

42. General quality of life of patients with acne vulgaris before and after performing selected cosmetological treatments Full Text available with Trip Pro

. In the study group, the acne changes occurred over the course of 3-15 years ([Formula: see text] years, SD =2.7 years). Selected cosmetological treatments (intensive pulsing light, alpha-hydroxy acids, cavitation peeling, needle-free mesotherapy, diamond microdermabrasion and sonophoresis) were performed in series in the number depending on the particular patient's chosen treatment, after excluding contraindications. General quality of life of the patients was estimated using the Skindex-29 and Dermatology

2017 Patient preference and adherence

43. Skin Ageing Signatures and Cancer

the skin of the face or forearm for instance acne, eczema, psoriasis, seborroheic dermatitis, herpes zoster. Currently receiving or having received in the last two months prior to study entry any of the following dermatological treatments for more than 8 days: hormone based cream, retinoid based facial cream, > 8% concentration alpha hydroxy acid based cream, topical steroids, antibiotics and antifungals Previous facial aesthetic treatments such as: lifting, chemical peeling, dermabrasion

2017 Clinical Trials

44. Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

, 2) calcipotriene or other Vitamin D preparations, or 3) topical retinoids. Patients who have used topical treatments, prescription or over the counter, including: Any topical atopic dermatitis therapeutic agents of any kind within the 2 weeks before baseline. Any topical corticosteroids within the 2 weeks before baseline. Any antibacterial, medicated and/or astringent washes, soaps, pads or moisturizers within 3 days before baseline. High strength (20% or above) alpha-hydroxy acid or any kind

2017 Clinical Trials

45. Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis

within 3 days before baseline. High strength (20% or above) alpha-hydroxy acid or any kind of peel or other procedures (e.g., laser hair removal) within 30 days before baseline. Any topical products (i.e., sunscreens, lotions, creams), except for bland emollient (moisturizer) within 24 hours before baseline. Topical antibiotics in the treatment area within 7 days before baseline. New regimens of beta blockers. Lithium preparations within 2 weeks before baseline. Anti-malarial agents within 2 weeks

2017 Clinical Trials

46. Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars

Signed and dated informed consent to participate in the study Exclusion Criteria: Presence of more than 3 scars per cheek (within the treatment area) of the following types: icepick scars or atrophic acne scars with a diameter of > 4 mm. Active acne with inflammatory component Use of per oral or topical (facial) substances containing retinoids, bensoyl peroxide, alpha-hydroxy acid at concentrations above 10%, beta-hydroxy acid at a concentration above 2%, or antibiotic treatment for active acne (...) Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: No-treatment control Other: No-treatment control No-treatment control Experimental: Treatment Intradermal injection Restylane Lidocaine Device: Restylane Lidocaine Hyaluronic acid based filler Outcome Measures Go to Primary Outcome Measures : Overall scar severity, assessed by blinded evaluator [ Time Frame: 3 months ] Secondary Outcome Measures : GAIS, assessed

2017 Clinical Trials

47. Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy

side will be considered. Exclusion Criteria: Patients with porphyria. Patients immunosuppressed for idiopathic, disease specific or therapeutic reasons. Use of topical corticosteroids to lesional areas within 2 weeks before PDT. Patients receiving local treatment (including cryotherapy and curettage, any - Patients receiving topical treatment (including imiquimod, 5-FU and diclofenac, Picato) in face / scalp area within the last 3 months. Use of topical retinoids or alpha-hydroxy acids, urea

2017 Clinical Trials

48. Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS

within the last 30 days.in Use of topical retinoids or alpha-hydroxy acids, systemic retinoids, chemotherapy or immunotherapy within 30 days of PDT. Pigmented AK lesion(s). Known allergy to Metvixia/Metvix, a similar PDT compound or excipients of the cream including arachis oil, or to peanut or soya. Participation in other clinical studies either currently or within the last 30 days. Female subjects must be of either: Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical

2017 Clinical Trials

49. Study of SOR007 Ointment for Actinic Keratosis

psychological illness. Significant history within the past year of alcohol or drug abuse. During the 30 day period preceding study entry: Participating in any clinical research; using topical paclitaxel for AK; using any other topical agents including but not limited to actinex, glycolic acid products, alpha-hydroxy acid products, and chemical peeling agents for the treatment of AK; using any systemic steroids or topical corticosteroids, having cryosurgery. Use of sun lamps or sun tanning beds or booths

2017 Clinical Trials

50. Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

) inhibitors, such as valproate or anticoagulants Taking any medication known to affect hedgehog (HH) signaling pathway such as itraconazole Within the past 6 months, has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study; specifically, these include the topical use to the study tumors of: Glucocorticoids Retinoids either systemically or topically (eg, etretinate, isotretinoin, tazarotene, tretinoin, adapalene) Alpha hydroxy acids (eg (...) , glycolic acid, lactic acid) to > 5% of the skin 5 fluorouracil or imiquimod and/or Itraconazole Has received treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling, within 60 days to starting study medication Currently receiving systemic medications that could affect BCC tumors (eg, oral retinoids) or might interact with remetinostat Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recurrent seizure history or psychiatric

2017 Clinical Trials

51. An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

. Subject had the need or planned to be exposed to artificial tanning devices or excessive sunlight during the study or had used artificial tanners within two weeks of Visit 1/Baseline. Subject had used any of the following topical medications on the face or scalp: Corticosteroids within two weeks of Visit 1/Baseline; Keratolytic-containing therapeutic products or medicated or irritant topical salves within two weeks of Visit 1/Baseline, including, but not limited to, alpha hydroxy acids (e.g., glycolic (...) acid, lactic acid etc. >5%), beta hydroxy acid (salicylic acid >2%), and urea >5%; Topical retinoids (e.g., tazarotene, adapalene, tretinoin) within two weeks of Visit 1/Baseline; Light treatments (e.g., psoralen plus ultraviolet A therapy, ultraviolet B) within four weeks of Visit 1/Baseline; Photodynamic therapy within eight weeks of Visit 1/Baseline; 5-fluorouracil, diclofenac, imiquimod, or ingenol mebutate within eight weeks of Visit 1/Baseline; or Other topical therapy for actinic keratosis

2017 Clinical Trials

52. Actinic Purpura

hands Extensor s Timing Lesions spontaneously resolve within 2 weeks (prolonged to 3 weeks in impaired phagocyte activity) VII. Management with UVA and UVB protection Medications that have been used for Actinic Purpura Alpha hydroxy Acids Arnica Oil Ceramides ( , ) Phytonadione ( 1) Combination product Moisturizing Product (DerMend) VIII. Complications Post-inflammatory IX. References communication with Joe Weidner, MD, received 10/3/2018 Images: Related links to external sites (from Bing

2018 FP Notebook

53. Chemical Peel

, Chemexfoliation II. Mechanism Chemical exfoliation of superficial skin layers using acids or enzymes (e.g. hydroxy acids) III. Indications (same indications as for Microdermabrasion) Benign epidermal pigmentation Rough skin Superficial acne scars IV. Dosing Course of 6 treatments every 4 weeks with maintenance treatments every 1-3 months V. Preparations Alpha hydroxy acids Lactid acid Beta hydroxy acids Salicylic acid VI. Efficacy Results are temporary VII. Advantages Inexpensive VIII. Disadvantages Difficult

2018 FP Notebook

54. Bladder Antispasmodic

to reduce bladder contractions by relaxing bladder smooth muscle. Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH SnomedCT 35768004 , 372717000 LNC LP18095-7, MTHU003379 English 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate , 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate , oxybutynin , OXYBUTYNIN @ @ UNIDENTIFIED , OXYBUTYNIN UNIDENTIFIED , Benzeneacetic Acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl Ester , 4 (...) therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. Concepts Pharmacologic Substance ( T121 ) , Organic Chemical ( T109 ) MSH SnomedCT 372768002 , 53641000 English Flavoxate , 4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester , Flavoxate [Chemical/Ingredient] , flavoxATE , flavoxate , FLAVOXATE , Flavoxate (product

2018 FP Notebook

55. They?re all the ?roid rage: origins and mechanisms of corticosteroid therapy.

and lactation. J Physiol, 1933. 77 (2): p. 159-73. 11. Hench, P.S., Potential Reversibility of Rheumatoid Arthritis. Ann Rheum Dis, 1949. 8 (2): p. 90-6. 12. Mc, K.B., G.W. Mc, and E.C. Kendall, Steroids derived from bile acids; the preparation of 3 (alpha)-hydroxy-Delta 11-cholenic acid from desoxycholic acid. J Biol Chem, 1946. 162 : p. 555-63. 13. Hench, P.S., E.C. Kendall, and et al., The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary (...) …”) and surgery (“How often has bona fide , if transient, relief appeared to follow tonsillectomy, only to fade after two or three weeks!”)—two states known to stimulate the adrenal cortex. As luck would have it, Dr. Edward Calvin Kendall, the director of biochemistry at Mayo who was already known for isolating thyroid hormone, had recently succeeded in isolating several different steroid hormones from both the adrenal cortex and from bile acids [12]. In April of 1949, Hench and Kendall published the first

2011 Clinical Correlations

56. The role of topical dermocosmetics in acne vulgaris. Full Text available with Trip Pro

, such as salicylic acid, lipo-hydroxy acid, alpha-hydroxy acids, retinol-based products and linoleic acid; agents targeting Propionibacterium acnes, such as lauric acid; and anti-inflammatory agents such as nicotinamide, alpha-linolenic acid and zinc salts. Despite the scientific advances in understanding these cosmetic ingredients, there still remains a lack of rigorous controlled studies in this area. © 2016 European Academy of Dermatology and Venereology.

2016 Journal of the European Academy of Dermatology and Venereology

57. Dose Response Study of GSK2330672 for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis

will be collected for evaluating total bile acid concentration as a biomarker of PBC Mean change from Baseline at Week 16 in serum 7-alpha hydroxy-4-cholesten-3-one (C4) [ Time Frame: Baseline and Week 16 ] Blood samples will be collected for evaluating C4 concentration as a marker of bile acid synthesis Plasma concentration of GSK2330672 after sparse sampling [ Time Frame: Week 8 and Week 12 (Between 1 and 3 hours post-dose, and between 5 and 8 hours post-dose) ] Blood samples will be collected for measurement (...) Frame: Baseline and Week 16 ] Participant's fatigue level will be recorded on an eDiary each evening using a 0 to 10 NRS. The Daily Fatigue Score is averaged over the 7 days preceding Baseline and over the 7 days preceding Week 16 Change from Baseline in the 5-D Itch Scale at Week 16 [ Time Frame: Baseline and Week 16 ] 5-D Itch Scale is measurement of participant's itch. Mean change from Baseline at Week 16 in serum total bile acid concentration [ Time Frame: Baseline and Week 16 ] Blood samples

2016 Clinical Trials

58. Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States

Exclusion Criteria: Age less than 18 years of age. Pregnant women. Non-English speaking patients. Treatment of actinic keratoses with other modalities including topical 5-fluorouracil, topical imiquimod, conventional PDT, alpha-hydroxy-acids, and glycolic acids within 2 months Use of retinoids within 1 month Use of the following medications: griseofulvin, thiazide diuretics, sulfonyureas, phenothiazines, sulfonamides, and tetracyclines History of cutaneous photosensitivity, lupus, porphyrias, or any (...) . Daylight PDT involves application of the photosensitizer in the physician's office followed by exposure to daylight. Condition or disease Intervention/treatment Phase Actinic Keratosis Non-melanoma Skin Cancer Drug: aminolevulinic acid HCl Not Applicable Detailed Description: The principal investigator will inform patients about the study during their initial consultation at the Mohs and Dermatologic Surgery Center, Dana-Farber/Brigham and Women's Cancer Center at Faulkner Hospital. The patients

2016 Clinical Trials

59. A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

Area within one (1) day prior to entry into the study. Subject used topical medications; corticosteroids, alpha hydroxy acids (e.g., glycolic acid, lactic acid etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, or prescription retinoids (e.g., tazarotene, adapalene, tretinoin) within the selected Treatment Area (trunk or extremities) within one (1) month prior to the Baseline Visit. Subject had cryodestruction, curettage

2016 Clinical Trials

60. MÄ’ Device for At-Home Skin Rejuvenation

to make no changes in their existing skincare regime, other than use of the study products, during the study period. If female, must be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Exclusion Criteria: Subjects who currently use or have used in the prior 30 days any skin products that contain alpha hydroxy (...) acids (AHA) e.g. glycolic, lactic, citric, or mandelic acid containing products or retinol/tretinoin containing products or exfoliating washes, masks or scrubs or other micro-dermabrasion skin care products on the treatment areas. Subjects who are unwilling to maintain their daily skin care regimen for the duration of the study. Subjects who have any skin pathology or condition that could interfere with the evaluation i.e. personal or family history of skin cancer, rosacea and/or requires the use

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>